- You are here:
- Home »
- Blog »
- colon cancer »
- Colon Cancer- FOLFOX vs CAPOX?
Colon Cancer- FOLFOX vs CAPOX?
My name is Bernie Davis. I have just been diagnosed with stage 3 colon cancer. I’m thinking through adjuvant chemotherapy- FOLFOX vs CAPOX. In particular, I’m thinking through:
- Efficacy,
- side effects,
- and 3 months vs. 6 months.
Both FOLFOX and CAPOX (also called XELOX) are standard, guideline-recommended regimens for adjuvant therapy. They have similar efficacy, but their side-effect profiles differ slightly because of the way the drugs are given and metabolized.
🔬 Regimen overview
| Regimen | Components | Administration |
|---|---|---|
| FOLFOX | 5-FU (fluorouracil) + leucovorin + oxaliplatin | IV infusion every 2 weeks, requires a port and pump |
| CAPOX (XELOX) | Capecitabine (oral 5-FU prodrug) + oxaliplatin | Oxaliplatin IV every 3 weeks + oral pills twice daily for 14 days |
⚖️ Comparative side-effect profiles
| Side effect | FOLFOX | CAPOX (XELOX) | Notes |
|---|---|---|---|
| Peripheral neuropathy(oxaliplatin-related) | Common (~40–50%), cumulative | Common (~40–50%), similar rate | Usually dose-limiting in both |
| Hand–foot syndrome | Rare | More common (10–20%) | Due to oral capecitabine; may require dose adjustment |
| Diarrhea | Moderate | More frequent/severe | Capecitabine causes more GI irritation |
| Mucositis (mouth sores) | More common | Less frequent | Related to continuous IV 5-FU exposure |
| Neutropenia / low WBC | More common | Less common | Continuous 5-FU suppresses marrow more |
| Fatigue | Similar | Similar | Often cumulative with oxaliplatin |
| Nausea / appetite loss | Slightly more with CAPOX | Usually manageable with antiemetics | |
| Hospital / clinic time | Requires infusion pump and 48-hr disconnection | Less time in clinic | Convenience advantage for CAPOX |
🧩 Summary
-
FOLFOX tends to cause more hematologic toxicity (neutropenia, mucositis).
-
CAPOX tends to cause more GI and skin toxicity (diarrhea, hand-foot syndrome).
-
Neuropathy risk from oxaliplatin is essentially the same in both regimens.
-
Convenience: CAPOX offers home-based oral dosing; FOLFOX requires an infusion pump.
-
3- vs 6-month duration: The IDEA pooled analysis found that for many stage III patients (especially T1–3N1), 3 months of CAPOX can be as effective as 6 months of FOLFOX, reducing neuropathy risk.
🩺 Practical takeaway
If you:
-
prefer fewer clinic visits and can reliably take pills → CAPOX may be better.
-
have sensitive GI function, kidney issues, or trouble swallowing pills → FOLFOX may be safer.
Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX
I’m not sure how to add another layer on top of the info above. I am researching diet, gut health and non-conventional therapies. But the above and below information helps me think through adjuvant therapy.
Are you a colon cancer patient? What do you think about adjuvant chemotherapy? Scroll down the page, post a question or a comment, and I will reply to you ASAP.
Thanks,
- Bernie Davis
- Colon Cancer Survivor
Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
Abstract
Background
Capecitabine and oxaliplatin (CAPOX) and folinic acid, fluorouracil, and oxaliplatin(FOLFOX) are both used in the adjuvant treatment of colon cancer, and while their efficacy is assumed to be similar, they have not been directly compared. We reviewed the toxicity profiles, relative dose intensity (RDI), and survival associated with these regimens across a multi-institutional cohort.
Patients and Methods
We identified 394 consecutively treated patients with stage III colon cancer who received an oxaliplatin-containing regimen. RDI was defined as the total dose received divided by the intended total dose if all cycles were received.
Results
FOLFOX was associated with increased mucositis (6.2% vs. 0.7%, P = .0069) and neutropenia (25.9% vs. 8.6%, P < .0001), while CAPOX was associated with increased dose-limiting toxicities (DLTs) (90.7% vs. 80.2%, P = .0055), diarrhea (31.8% vs. 9.0%, P < .0001), and hand–foot syndrome (19.9% vs. 2.1%, P < .0001).
Higher median RDI of fluoropyrimidine (93.7% vs. 80.0%, P < .0001) and oxaliplatin (87.2% vs. 76.3%, P < .0001) was noted for patients receiving FOLFOX.
Reducing the duration from 6 to 3 months would have prevented 28.7% of FOLFOX and 20.5% of CAPOX patients from ever experiencing a DLT (P = .0008).
Overall survival did not differ by regimen (hazard ratio = 0.73; 95% confidence interval 0.45-1.22; P = .24). However, CAPOX was associated with improved disease-free survival (3-year disease-free survival 83.8% vs. 73.4%, P = .022), which remained significant in high-risk (T4 or N2) (P = .039) but not low-risk patients (P = .19).
Conclusion
CAPOX may be associated with improved disease-free survival despite greater toxicities and lower RDI. Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT.
FOLFOX vs. CAPOX FOLFOX vs. CAPOX